tirofiban
Sign in to saveAlso known as L-700462, MK-383, (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid, N-(butylsulfonyl)-O-[4-(4-piperidyl)butyl]-L-tyrosine
Tirofiban, sold under the brand name Aggrastat, is an antiplatelet medication. It belongs to a class of antiplatelets named glycoprotein IIb/IIIa inhibitors. Tirofiban is a small molecule inhibitor of the protein-protein interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa and is the first drug candidate whose origins can be traced to a pharmacophore-based virtual screening lead.
Key facts
- Drug.verifiedrevid
- 470610777
- Drug.image
- Tirofiban.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 290
- Drug.image2
- Tirofiban ball-and-stick.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Aggrastat
- Drug.MedlinePlus
- a601210
- Drug.DailyMedID
- Tirofiban
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- intravenous
- Drug.ATC_prefix
- B01
- Drug.ATC_suffix
- AC17
- Drug.legal_US
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.protein_bound
- 65%
- Drug.elimination_half life
- 2 hours
- Drug.IUPAC_name
- (2S)-2-[(butylsulfonyl)amino]-3-{4-[4-(piperidin-4-yl)butoxy]phenyl}propanoic acid
via Wikipedia infobox
Research
2,021 papers- Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.The New England journal of medicine · 2025
- Tirofiban-induced thrombocytopenia.Annals of medicine · 2023
- Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.JAMA neurology · 2024
- Tirofiban in emergency conditions.The American journal of emergency medicine · 2022
- Tirofiban in Acute Ischemic Stroke: Mechanistic Rationale, Clinical Advances, and Emerging Therapeutic Strategies.Drugs · 2025
via PubMed
~6 min read
Encyclopedic overview
12 sectionsContents
- Medical uses
- Contraindications and precautions
- Adverse reactions
- Use in pregnancy
- Pediatric use
- Other precautions and laboratory exams
- Side effects
- Interactions
- Pharmacology
- Chemistry
- History
- References
Tirofiban, sold under the brand name Aggrastat, is an antiplatelet medication. It belongs to a class of antiplatelets named glycoprotein IIb/IIIa inhibitors. Tirofiban is a small molecule inhibitor of the protein-protein interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa and is the first drug candidate whose origins can be traced to a pharmacophore-based virtual screening lead.
It is available as a generic medication.
Excerpted from Wikipedia’s “tirofiban” article, available under the CC BY-SA 4.0 licence.